Litfulo (ritlecitinib) for vitiligo: investigational evidence and risks

Current commercial access is for an approved alopecia indication. Vitiligo access would therefore be research or off-label care unless a regulator later authorizes it, and a prescription would not guarantee coverage. Specialist visits, screening, laboratory work, interaction review, follow-up, and payer decisions add burden.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

A phase 2 extension compared 43 people in an add-on narrowband-UVB group with 187 receiving ritlecitinib alone. At extension week 24, 44.4% versus 27.4% reached F-VASI75 when missing values used last observation carried forward; that difference was not statistically significant. In the observed-case analysis, 60.9% versus 29.2% reached F-VASI75 and the difference was statistically significant. The add-on group had a stopping rule that the other group did not. These analysis-dependent results cannot establish combination superiority or define a routine sequence.⌁ Evidence

The sources I read are missing the full peer-reviewed phase 3 response and safety tables. They are also missing durability, phase 3 subgroup findings, and reliable outcomes for hands, feet, or other individual sites. Patient stories can identify burden and priorities, but they cannot establish typical benefit, safety, approval, or who should take a systemic medicine.⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence⌁ Evidence

Litfulo's current US label sets one authorized dose for its approved severe-alopecia-areata indication: 50 mg by mouth once daily, with no loading dose. No regulator reviewed here has authorized any vitiligo dose or schedule, unlike Rinvoq's EU-authorized vitiligo dose. The phase 2 vitiligo trial measured its facial result at week 24. Pfizer's phase 3 topline reported both studies meeting their co-primary endpoints at week 52, about a year after starting, not sooner.⌁ Evidence⌁ Evidence⌁ Evidence

Pfizer's own patient-access page describes a copay card for Litfulo's approved severe-alopecia-areata use. Eligible patients with commercial insurance may pay as little as $0 a month. The annual maximum runs $4,000 to $15,000 across as many as 13 fills a year. The card excludes anyone enrolled in Medicare, Medicaid, TRICARE, or Veterans Affairs care, and is not valid for cash-paying patients. A separate Pfizer Interim Care Rx program can supply the medicine at no cost for up to two years. It is for eligible, commercially insured patients facing a coverage delay or denial, and it excludes residents of Massachusetts and Michigan. I went to cash-price trackers after direct GoodRx and Drugs.com fetches were both blocked. They report a 28-capsule supply of Litfulo 50 mg priced from about $4,290 to about $4,691, without any discount applied.⌁ Evidence⌁ Evidence⌁ Evidence

Litfulo is FDA-approved for severe alopecia areata, so a US vitiligo prescription would be off-label, not unapproved outright. Off-label use goes through its own insurance review, separate from an approved use. One commercial insurer’s own published policy shows how that review works for a non-cancer request. It first checks a recognized drug compendium, such as DrugDex. Next it checks a national cancer-drug compendium. Last it checks for a published phase 3 randomized trial. A request that clears none of those steps is denied as experimental or investigational. That same policy treats a Medicare Part D request more narrowly: it accepts only two named compendia there, and a published trial alone does not qualify. Step therapy can still apply after an off-label request is approved.⌁ Evidence

People I have heard from get stuck on which option to choose, with so many now in the mix. No reader has sent me a first-hand account of Litfulo for vitiligo yet, and I have no documented pattern of what people taking it describe. Litfulo has no vitiligo indication, so most current patient experience with the drug itself comes from its approved alopecia-areata use, not vitiligo. I will not invent an account. This answer will grow as reader accounts come in.⌁ Evidence

If you are in a trial or considering off-label use, keep a dated log of each dose and any missed day. Note any new or worsening symptom, especially an infection sign, since the boxed warnings and monitoring plan above depend on catching those early. Log each screening and lab visit your prescriber or study team sets. The safety conversation above needs ongoing blood-count, liver, and infection review, not a one-time check. Add a same-conditions photo - same light, distance, and angle - near the phase 2 trial's week-24 assessment point. Add another near week 52, the timeline the phase 3 studies used for their own result.⌁ Evidence⌁ Evidence⌁ Evidence